Graig Suvannavejh
Stock Analyst at Mizuho
(4.55)
# 238
Out of 5,162 analysts
175
Total ratings
55.3%
Success rate
21.08%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $19 → $20 | $18.39 | +8.75% | 12 | Mar 5, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $136.60 | +83.02% | 2 | Feb 25, 2026 | |
| INSM Insmed | Maintains: Outperform | $211 → $204 | $139.52 | +46.22% | 13 | Feb 24, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $7.50 | +33.33% | 1 | Feb 19, 2026 | |
| IMMX Immix Biopharma | Initiates: Outperform | $14 | $10.14 | +38.07% | 1 | Feb 9, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $14.65 | -65.87% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $44.24 | +22.06% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $169.55 | +14.42% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $27.79 | +65.53% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $68.17 | +46.69% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $9.41 | +144.42% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $63.56 | -11.89% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $32.83 | +40.12% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $154.12 | +31.07% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.55 | +158.06% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.30 | +10,007.82% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.23 | +56.95% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.14 | +59.24% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.45 | +83.49% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $16.01 | -31.29% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $14.03 | +85.32% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $14.38 | -44.37% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $31.04 | +6.31% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.46 | +420.55% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.59 | +671.64% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.74 | -63.50% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $91.15 | -61.60% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $23.79 | -66.37% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $60.00 | -5.00% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $26.94 | -81.44% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $10.48 | +224.58% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $10.02 | +179.44% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $29.94 | +3.54% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $14.05 | +2,604.63% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.50 | +216.67% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $22.91 | +57.14% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $31.93 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $3.37 | +997.92% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $180.32 | -29.02% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Mar 5, 2026
Maintains: Neutral
Price Target: $19 → $20
Current: $18.39
Upside: +8.75%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $136.60
Upside: +83.02%
Insmed
Feb 24, 2026
Maintains: Outperform
Price Target: $211 → $204
Current: $139.52
Upside: +46.22%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $7.50
Upside: +33.33%
Immix Biopharma
Feb 9, 2026
Initiates: Outperform
Price Target: $14
Current: $10.14
Upside: +38.07%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $14.65
Upside: -65.87%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $44.24
Upside: +22.06%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $169.55
Upside: +14.42%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $27.79
Upside: +65.53%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $68.17
Upside: +46.69%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $9.41
Upside: +144.42%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $63.56
Upside: -11.89%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $32.83
Upside: +40.12%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $154.12
Upside: +31.07%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.55
Upside: +158.06%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.30
Upside: +10,007.82%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.23
Upside: +56.95%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.14
Upside: +59.24%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.45
Upside: +83.49%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $16.01
Upside: -31.29%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $14.03
Upside: +85.32%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $14.38
Upside: -44.37%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $31.04
Upside: +6.31%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.46
Upside: +420.55%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.59
Upside: +671.64%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.74
Upside: -63.50%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $91.15
Upside: -61.60%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $23.79
Upside: -66.37%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $60.00
Upside: -5.00%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $26.94
Upside: -81.44%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $10.48
Upside: +224.58%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $10.02
Upside: +179.44%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $29.94
Upside: +3.54%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $14.05
Upside: +2,604.63%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.50
Upside: +216.67%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $22.91
Upside: +57.14%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $31.93
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $3.37
Upside: +997.92%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $180.32
Upside: -29.02%